1-4 of 4
Kathleen Colson, RN
Close
Sort by
Journal Articles

Final Phase I Results of Perifosine In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed or Refractory Multiple Myeloma (MM)

Andrzej J Jakubowiak, MD, PhD, Paul G Richardson, MD, Todd M Zimmerman, MD, Melissa Alsina, MD, Jonathan L. Kaufman, MD, Malathi Kandarpa, PhD, Colleen K. Harvey, Kathleen Colson, RN, BSN, BS, Monica Mitchell, RN, OCN, Teru Hideshima, MD, PhD, Peter Sportelli, Lesa Gardner, RN, Kathy Giusti, MBA, Kenneth C. Anderson, MD
Journal: Blood
Blood (2010) 116 (21): 3064.
https://doi.org/10.1182/blood.V116.21.3064.3064
Published: 2010
Journal Articles

Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up

Paul G Richardson, MD, Sundar Jagannath, MD, Andrzej J Jakubowiak, MD, PhD, Sagar Lonial, MD, Noopur Raje, MD, Melissa Alsina, MD, Irene Ghobrial, MD, Robert L. Schlossman, MD, Amitabha Mazumder, MD, Nikhil C. Munshi, MD, David H. Vesole, MD, PhD, Kathleen Colson, RN, BSN, BS, Mary L McKenney, MSN, Laura E Lunde, BA, John Feather, Teru Hideshima, MD, PhD, Robert D Knight, MD, Dixie-Lee Esseltine, MD, FRCPC, Constantine S. Mitsiades, MD, PhD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2010) 116 (21): 3049.
https://doi.org/10.1182/blood.V116.21.3049.3049
Published: 2010
Journal Articles

Updated Results of a Phase I Study of RAD001 In Combination with Lenalidomide In Patients with Relapsed or Refractory Multiple Myeloma with Pharmacodynamic and Pharmacokinetic Analysis

Anuj Mahindra, MD, Paul G Richardson, Parameswaran Hari, MD, Aliyah R. Sohani, MD, Jacob P. Laubach, MD, Jill Burke, NP, Sarah Kaster, Christine Connolly, Linda Rivera, Paulette Jacobs, Ayman Saad, MD, Kathleen Colson, RN, Irene Ghobrial, MD, Robert L. Schlossman, MD, Jennifer Adams, Wendy Makrides, Edie Weller, Nikhil C. Munshi, MD, Kenneth C. Anderson, Noopur Raje, MD
Journal: Blood
Blood (2010) 116 (21): 3051.
https://doi.org/10.1182/blood.V116.21.3051.3051
Published: 2010
Journal Articles

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.

Paul Richardson, MD, Sundar Jagannath, MD, Andrzej Jakubowiak, MD, PhD, Sagar Lonial, MD, Noopur Raje, MD, Melissa Alsina, MD, Irene Ghobrial, MD, Amitabha Mazumder, MD, Nikhil C Munshi, MD, David H Vesole, MD, PhD, Kathleen Colson, RN, BSN, BS, Mary L McKenney, Laura Lunde, BA, Sarah Kennedy, BS, Kara Kosakowski, Constantine Mitsiades, MD, PhD, Teru Hideshima, MD, PhD, Robert D Knight, MD, Dixie-Lee Esseltine, MD, Kenneth C Anderson, MD
Journal: Blood
Blood (2008) 112 (11): 1742.
https://doi.org/10.1182/blood.V112.11.1742.1742
Published: 2008